Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) EBIAT: 2017-2018

Historic EBIAT for Astria Therapeutics (ATXS) over the last 2 years, with Dec 2018 value amounting to -$6.1 million.

  • Astria Therapeutics' EBIAT fell 10.24% to -$6.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$25.9 million, marking a year-over-year increase of 5.46%. This contributed to the annual value of -$25.9 million for FY2018, which is 5.46% up from last year.
  • As of Q4 2018, Astria Therapeutics' EBIAT stood at -$6.1 million, which was down 6.71% from -$5.7 million recorded in Q3 2018.
  • Astria Therapeutics' EBIAT's 5-year high stood at -$5.5 million during Q4 2017, with a 5-year trough of -$7.9 million in Q1 2017.
  • Moreover, its 2-year median value for EBIAT was -$6.7 million (2017), whereas its average is -$6.7 million.
  • The largest annual percentage gain for Astria Therapeutics' EBIAT in the last 5 years was 19.07% (2018), contrasted with its biggest fall of 10.24% (2018).
  • Astria Therapeutics' EBIAT (Quarterly) stood at -$5.5 million in 2017, then decreased by 10.24% to -$6.1 million in 2018.
  • Its last three reported values are -$6.1 million in Q4 2018, -$5.7 million for Q3 2018, and -$6.5 million during Q2 2018.